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Background: A variety of large randomized controlled trials (RCT’s) evaluating pharmacotherapy in chronic
obstructive pulmonary disease (COPD) patients does exist. One of the drugs that has been tested is the new
long-acting anticholinergic glycopyrronium bromide.
Methods: As the generalizability of results from RCT’s is questionable we designed a longitudinal, prospective
non-interventional study (DACCORD) of two years duration plus two years extension with at least 6000 participants
in approximately 500 primary and secondary care practices in Germany (within the new established COPD National
Prospective Registry), to assess patient reported outcomes (PRO’s), lung function, adherence and drug safety. To
circumvent the hurdle of inappropriate COPD diagnosis in a non-interventional trial, patients have to fulfill the
inclusion criteria of the COPD disease management program (DMP) of the German statutory health insurances.
Patient management should follow the German national COPD guidelines, which are based on Global Initiative
for Chronic Obstructive Lung Disease 2007 (GOLD) report. Labels of prescribed drugs should also be taken into
account. Patients received treatment as part of their standard care: at the discretion of the investigator patients
were included in one of two arms. A: standard care with glycopyrronium containing regimen, and arm B: standard
care without glycopyrronium.
Discussion: For 2016 we expect important results regarding longitudinal development of PRO’s including
exacerbations, lung function, adherence and side effects. We also investigate applicability of the new GOLD staging
system in usual care. Data on diagnostic and treatment modalities in current German primary and secondary care,
as well as pharmaco-economic data will be generated.
Trial registration: 1. German Register for non-interventional studies: http://www.vfa.de/de/arzneimittel-forschung/
datenbanken-zu-arzneimitteln/nisdb.
2. EMA EnCePP http://www.encepp.eu/.
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Chronic obstructive pulmonary disease is a major cause
of morbidity and mortality worldwide; in Germany its
overall prevalence in the population over 40 years is as
high as 13.3% [1] and clearly increasing with age up to
40.4% in men older than 70 years. Thus, aging itself is a* Correspondence: kardos@lungenpraxis-maingau.de
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unless otherwise stated.risk factor for COPD, continuing increase in prevalence
in an ageing population is expected [2].
Since the early nineteen sixties COPD was recognized
as an important health problem, even if initially different
hypotheses and definitions applied: the Dutch hypothesis
[3], as opposed to the British [4] until 2001 the Global Ini-
tiative for Obstructive Lung Disease (GOLD) defined
COPD as “ airflow limitation that is not fully reversible …
and usually …progressive” [5]. Data on the natural history
of COPD, as measured by the annual rate of FEV1 (forced
expiratory volume in 1 second) decline are scant [6] andThis is an Open Access article distributed under the terms of the Creative
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of decline but also increases in FEV1 in some patients [7].
There is evidence, that the decline is related to the base-
line lung function [8,9]. In the last decade it was increas-
ingly recognized, that beyond FEV1 as a marker of disease
severity other important variables determine the course of
the disease: symptoms i.e. breathlessness, activity limita-
tions, exacerbations [10] and, importantly co-morbidities
[11]. However, to our best knowledge no data exist on
the natural history of COPD under real life treatment
conditions in the community (i.e. elderly patients, fre-
quently with several co-morbidities likely with large im-
pact on COPD outcome) so far.
Taking recent expansion of knowledge on the patho-
genesis of COPD into account the 2011 version of the
GOLD report introduced an entirely new and as yet
controversial [12-16] complex system of assessing COPD
based on symptoms, spirometry and exacerbation risk.
Therefore, we set up a large, nationwide COPD regis-
try and at the same time initiated a prospective non-
interventional study DACCORD of 2 years duration
with optional further 2 years of extension. The study
will primarily focus on patient related outcomes (PRO’s)
in real life patients, treated in both primary and/or sec-
ondary care. Further assessments include exacerbations
(frequency and time to first) and lung function vari-
ables. Beyond that, the design of the study will enable
an evaluation either according to the old GOLD I-IV or
the new GOLD ABCD grading system, which allows ap-
propriate juxtaposition in the results.
According to both the old and new GOLD treatment
recommendations long acting bronchodilators are the
backbones of the treatment of COPD. In 2012 a new
once-daily long-acting antimuscarinic (LAMA) glycopyr-
ronium was introduced on the German market. The DAC-
CORD study should also provide both post-authorization
safety study (PASS) data for the European Medicine
Agency (EMA) if needed and real life effectiveness data on
pharmacologic treatment in accordance with guidelines.
Methods
Study design
DACCORD is an ongoing 2–4 yr non-interventional
longitudinal prospective cohort study being conducted
in 6000 patients at 500 centres in Germany. To further
evaluate the therapeutic effects particularly of new and
innovative medicinal products as part of standard COPD
care in Germany, the study will consist of a group A:
standard care with glycopyrronium containing regimen,
and group B: standard care regimen without glyco-
pyrronium. Randomization is not possible in a non-
interventional study. Our overall target was however, to
achieve an approximately 2:1 distribution. Each investi-
gator was provided with an eCRF account to includepatients in a 2:1 manner (group A: group B). However,
after calling the CRO the investigator was able to modify
this distribution. Having made a decision on any change in
the treatment of an eligible COPD patient (s. below) the in-
vestigator included the patient in the respective study arm.
This procedure enables collection of sufficient safety and
real-life efficacy data of glycopyrronium. Thus, included
patients in both arms were treated at the discretion of the
physician, but following the German National Guideline
NVL COPD (http://www.awmf.org/uploads/tx_szleitlinien/
nvl-003l_S3_COPD_abgelaufen.pdf) and the label of the
drugs prescribed.
Following a baseline visit, subjects are to be followed-
up for at least 2 years, in approximately three months
intervals. Thereafter 2 additional visits are planned at 3
and 4 years, respectively.
The study is being conducted in accordance with the
Declaration of Helsinki, and has been approved by the
ethics committee of the Friedrich-Alexander University
Erlangen-Nuremberg.
Study objectives
The main objective of the registry is the documenta-
tion, description and optimization of diagnostic and
therapy of out-patient treated patients suffering from
COPD in Germany. Further specific objectives will be
evaluated:
1. To measure individual PRO’s i.e. dyspnea,
symptoms, exacerbations by means of validated
questionnaires CAT (COPD Assessment Test),
mMRC (modified Medical Research Council scale),
and weighted symptoms according to the new PRO
questionnaire [17]).
2. To document exacerbations retrospectively before
(6 month preceding inclusion) and prospectively
(number, severity, treatment, time to next
exacerbation) after inclusion.
3. To evaluate comorbidities (number, type, impact).
4. To analyze longitudinal changes in lung function
including FEV1 decline.
5. To establish safety and tolerability of the
treatments AE’s (adverse event), SAE’s (severe
adverse event).
6. To assess the implementation of pharmacological
treatment recommendations in German COPD
guidelines at the participating centres.
7. To assess type of diagnostic measures performed
during an outpatient visit.
8. To evaluate potential differences in the treatment of
COPD between primary and secondary care.
9. To gather pharmaco-economic data.
10. To assess the potential impact of rapid onset of
effect of glycopyrronium in the practical setting.
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COPD treatments (as measured by refill rates).
12. To evaluate the dropout rate.
Patients
All consecutive patients with COPD in participating cen-
tres should be considered for study enrolment in line
with the inclusion/exclusion criteria if – at the discretion
of the physician - they needed modification of their
established antiobstructive treatment (Group A) or if a
glycopyrronium-based therapy was started for treatment
modification (Group B).
In order to guarantee the best possible selection under
the conditions of a non-interventional study, only pa-
tients were eligible if they fulfilled recruitment criteria
for DMP-COPD of the German statutory health insur-
ance system. This strategy ensured, that – independently
from investigator site – only spirometrically proven
COPD patients were included in the multicentre real life
study.
These eligibility criteria include:
– Age ≥ 40 years;
– Post bronchodilator FEV1/VC ratio <70%
– Change in FEV1 post bronchodilator – pre
bronchodilator <15% or 200 ml (for reversibility also
historical data were accepted).
– Alternatively: Static hyperinflation and increase in
airway resistance measured by bodyplethysmography
in patients with FEV1/VC (vital capacity) ratio >70%.
Moreover, doctor diagnosed COPD was also required.
Despite DACCORD being a non-interventional study pa-
tients have to be willing and able to give informed consent
for participation and pseudonymized study data collection.
Exclusion criteria are only ongoing participation in a
randomized controlled trial and recruitment to DMP
Asthma.
Outcome measurements
At baseline (Visit 0) sociodemographic data (e.g. sex,
year of birth, height and weight) and medical data e.g.
physical exam, history including smoking status, exacer-
bations, vaccination status (influenza and pneumococ-
cae), spirometry including reversibility test, the presence
of co-morbidities, current COPD therapy including non-
pharmacological treatment and concomitant non-COPD
medication will be collected and registered electronically
at the treatment site and stored in pseudonymised
format in a secure, non-public database (see below).
Furthermore each patient will be asked to complete the
CAT, the mMRC and the new PRO symptoms question-
naire [17]. The collection of symptoms, measured by CAT
and mMRC, history of exacerbations and spirometryassessment will allow the patients’ categorization accord-
ing to the GOLD stages 2011, also in comparison with
GOLD stages 2007.
At the next appointment after about three months
according to the usual treatment interval in the COPD
German Disease Management Program (visit 1), the out-
come of the treatment modification or new treatment
will be evaluated using the PRO questionnaire. Further-
more, changes in medication and exacerbations, hospital
admissions and adverse events or serious adverse events
and their outcome will be documented at each of the
quarterly follow-up visits (visits 2, 3, 5–7). After one year
(visit 4) and two years (visit 8), parameters will be docu-
mented in line with Visit 0. Further annual visits after
three and four years, respectively, are optional (Figure 1).
While AE’s and SAE’s will be collected at each visit
on standardized electronically forms, in case of adverse
events of particular interest (cardiac events; e.g. ischaemic
heart diseases, cardiac arrhythmias, cardiomyopathies and
events associated with narrow-angle glaucoma), additional
information concerning the event will be documented.
After such events have occurred, corresponding question-
naires will be provided by Novartis Pharma GmbH – De-
partment of Drug Safety on a case-by-case basis.
Statistical considerations
Sample size calculation and population
There are approximately 930 respiratory physicians in
Germany. At least 300 are likely to participate in this
study, corresponding to about 33% of the above group
and therefore ensuring representative coverage.
In order to make a comparative analysis of the ap-
proaches of different groups of doctors to the treatment
of COPD, at least 100 general practitioners (specializing
in pulmonology, defined as the possibility to conduct
spirometry at the surgery) should additionally participate
in the study. An average of 15 patients per centre are ex-
pected to be enrolled, producing a total sample size of 6
000 patients. The distribution of the centres and the
planned number of patients will ensure a representative
picture of outpatient treatment for COPD in Germany.
Furthermore, because the patient number is large, a
number of relevant subsets can be identified and de-
fined (e.g. older patients, women/men, patients with
frequent exacerbations, patients with comorbidities, COPD
stages, etc.).
Statistical analyses
In order to permit comparisons between the two study
arms (with and without glycopyrronium, respectively),
propensity score stratification will be performed. The
main risk factors included therein are age, sex distribu-
tion, COPD severity, smoking status, number of exacer-
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Figure 1 DACCORD Study time table.
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using the ITT (intend-to-treat) and PP (per-protocol,
participants in accordance with all inclusion/exclusion
criteria) population. All the parameters recorded will be
analyzed descriptively. However, systematic group differ-
ences with respect to prognostic factors must be antici-
pated in a non-randomized study, leading to bias from
confounding. Epidemiological analyses techniques to
avoid confounding (e.g. propensity score matching or
matched-pair analysis) might lead to selectively choosed
patients and thereby additionally decrease sample size
within certain groups. For these kind of analyses the
credibility increases with the amount of patients en-
rolled. Under real-life-setting as in this study, the size of
subgroups cannot be controlled but will correspond to
the true distribution of these characteristics in the target
population and thus might lead to small sample sizes in
uncommon subgroups.
Study organization
The study was designed and guided by the study steering
committee consisting of a principal investigator and 4
respiratory physicians, working in both hospital and
secondary care outpatient setting. Electronic data are
collected at the study sites, data transfer, management and
storage, quality control rest on the independent Lung
Research Institute (ILF GmbH) of the German Respiratory
Society. Statistical plan and evaluation will be provided
by an independent service. The documentation of the
data will be verified by on-site source-data verification
at about 5% of the centres per year. The study is regis-
tered at http://www.vfa.de/de/arzneimittel-forschung/
datenbanken-zu-arzneimitteln/nisdb.
DACCORD is fully sponsored by Novartis Pharma
GmbH, Germany.
Discussion
The non-interventional real life study design of DAC-
CORD aims at bridging the gap between randomized
controlled trials and clinical reality. Archibald Cochranewrote: “Between measurements based on randomized
controlled trials and benefit …in the community there is
a gulf which has been much under-estimated” [18]. In fact,
RCT’s are the most favorable way to assess therapeutic ef-
fect versus placebo or versus established treatment with
high internal validity; however the external validity may be
low. Thus, assessing the effect of a drug both RCT’s and
natural studies including non-interventional studies are
necessary [19,20].
Hence, going beyond the results of randomized clinical
trials with the non-interventional setting of DACCORD,
the main strengths of the study are:
1 Size of the study population and long-term follow-up
time period
Most epidemiological studies are cross-sectional by de-
sign or at best perform a pre-/post-analysis focusing on a
particular question like guideline adherence [21]. Little
data are available on repeated evaluations using identical
methods and the same population obtained at a defined
time point, although recent publications indicate the
growing significance of data from observational studies
[19,22]. To our best knowledge no longitudinal studies in
COPD patients with comparable size according to both
the number of recruiting physicians and included COPD
patients have been published, another similar study Can-
adian Cohort of Obstructive Lung Disease (CanCOLD) is
just ongoing [22].
The longitudinal character allows for assessments of real
life decline in lung function under usual care, quality of
life changes, exacerbations, adherence and dropout.
2 Broad inclusion criteria
Most pivotal pharmacologic trials still exclude usual
real life patients with COPD suffering from significant
co-morbidities [23,24]. Even after more than a decade of
successful marketing realistic data of side effects of the
most popular COPD treatments are not readily available,
Kardos et al. BMC Pulmonary Medicine 2015, 15:2 Page 5 of 6
http://www.biomedcentral.com/1471-2466/15/2resulting in questionable estimations of - for example
cardiovascular side effects [25,26]. To our knowledge
just one ongoing RCT is targeted to recruit and treat
COPD patients with cardiovascular co-morbidity [27].
The natural character of the DACCORD study will
expand currently available knowledge derived almost
exclusively from controlled trials with narrow inclusion/
exclusion criteria, performed in highly selected patients
eliciting low external validity.
3. Implementation of DMP criteria as inclusion
criterion
Large, post marketing non-interventional studies in re-
spiratory medicine - partly conducted by family physi-
cians - frequently suffer from inclusion of inappropriate
patients not fulfilling the indication for the respective
treatments and therefore leading to lower evidence of
the results. In order to minimize potential risk of in-
sensitive patient selection resulting in decrease of data
quality, included patients need to fulfill the criteria of
the disease management program (DMP) of COPD. Sev-
eral DMP programs were implemented by the statutory
health insurances in 2001 to further improve the treat-
ment of patients with chronic diseases, e. g. diabetes or
COPD. By performance of this inclusion criterion, all pa-
tients had had quality controlled appropriate lung func-
tion tests. All COPD patients with flow limitation and
aged above 40 years are eligible for the DMP-COPD.
However, some COPD patients with high (more than
15%) reversibility are at the time of the study recruit-
ment not eligible for DMP-COPD, thus, not eligible for
DACCORD. For patients treated in German surgeries
this criterion ensures the external validity of the study.
Another important result of this study could be
the comparison of the old and the new GOLD staging
system applied in a large, well characterized prospective
cohort. Will the complex GOLD ABCD system better
predict patient related outcomes? Does real life medica-
tion fit better with the old or with the new staging
system?
Both arms of the study will be analyzed statistically, as
mentioned to generate data on real life effectiveness of
glycopyrronium as monotherapy or combination treat-
ment. Furthermore, a sample size of 6000 patients will
allow performing adequately powered subgroup analyses
on different pharmacological COPD treatment strategies.
Data for comparative effectiveness research will be also
generated by means of analyses of accordance with guide-
lines and labels. Due to the high number of physicians and
patients a reliable comparison between the two most
important provider groups for respiratory diseases (family
physicians and secondary respiratory care physicians) will
be also possible.If compared with register studies extracted from health
insurance provider databases, the prospective character
and the better identification and characterization of
the target population, the inclusion of important but in
insurance databases not readily available medical data,
i.e. smoking habits, exacerbations, lung function is a
great advantage.
A further strength of the study is the independent data
management and statistical analysis by the Lung Research
Institute founded by the German Respiratory Society on
the one and the management of adverse events by the
professional drug safety department of Novartis Germany
on the other hand.
Patient enrolment started in November 2012; we await
final results of main analyses in the first quarter 2016.
Interim one year data will be available 2015.
In conclusion one of the largest ongoing prospective
non-interventional studies could generate new, real life
patient related, lung function and health care related
data and answer important yet open questions to different
aspects of COPD care.
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